Sareum Holdings Plc (LON:SAR) has selected another candidate molecule from its TYK2 inhibitor programme to take through the clinic, this time as a potential therapy for certain cancers.
Earlier this month, the AIM company went with SDC-1801 as a &l…
Sareum Holdings Plc (LON:SAR) has highlighted the progress made by its in-house and out-licensed drug programmes over the past year.
US firm Sierra Oncology, which is the licence holder of Sareum’s SRA737 checkpoint kinase 1 (Chk1) inhibitor …
@Sareumplc Latest tweet
Roche's discontinuation of its CHK1 inhibitor, RG7741 (aka Genentech's GDC-0575), means this mechanism is now a two… https://t.co/xq9zzVT44p